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Repeated evidence has demonstrated that combined primer-booster immunization regimens can improve
both secreted and humoral immune responses to antigens derived from viral, bacterial, and parasitic patho-
gens. For the present work, we evaluated the synergic serum immunoglobulin G (IgG) and fecal IgA antibody
responses elicited in BALB/c mice who were intramuscularly primed with a DNA vaccine, pRECFA, followed
by oral boosting with an attenuated Salmonella enterica serovar Typhimurium vaccine (HG3) strain, with both
vaccines encoding the structural subunit (CfaB) of the CFA/I fimbriae produced by human-derived entero-
toxigenic Escherichia coli (ETEC) strains. The immunological properties of the vaccine regimen were evaluated
according to the order of the administered vaccines, the nature of the oral antigen carrier, the age of the
vaccinated animals, the interval between the priming and boosting doses, and the amount of injected DNA. The
production of gamma interferon and the IgG2a subclass in serum indicated that mice immunized with the
primer-booster regimen developed prevailing type 1 T-cell-dependent immune responses. The synergic effect of
the vaccine regimen on the induced antibody responses was also revealed by its ability to block the adhesive
properties of CFA/I fimbriae expressed by live bacteria, as shown by the inhibition of Caco-2 cell and human
erythrocyte binding. Moreover, DBA2 newborn mice were protected from lethal challenges with a CFA/I
ETEC strain after the incubation of live bacteria with serum samples harvested from mice who were subjected
to the primer-booster regimen. We propose, therefore, that the DNA primer-Salmonella booster regimen
represents an alternative for the development of vaccines requiring both mucosal and systemic antibody
responses for immunological protection.
The stimulation of mammalian immune systems by the ad-
ministration of DNA vaccines encoding heterologous antigens
has been repeatedly demonstrated to efficiently activate hu-
moral and cellular immune responses to various infectious
agents and tumors (9, 19). Nonetheless, it is also well known
that one of the main limitations of genetic vaccines is their
limited capacity to induce specific secreted antibody responses
at intestinal or respiratory epithelia of animals that are immu-
nized via parenteral routes. Consequently, several approaches
have been designed to circumvent the limited mucosal immu-
nogenicity of DNA vaccines, such as direct delivery of DNA to
mucosal sites (23, 26, 30), incorporation of DNA into lipo-
somes or biodegradable polymers (22, 25), coadministration of
plasmids expressing cytokine or costimulatory molecules (12,
42), in vivo transfection mediated by attenuated bacterial vec-
tors (8, 13), and primer-booster immunization regimens (11,
41).
So far, most primer-booster immunization strategies based
on DNA vaccines have targeted the induction of cellular and
humoral systemic immune responses and have usually em-
ployed a DNA vaccine for priming and recombinant viruses or
purified proteins for boosting (24, 28, 34, 36, 37, 40). The
direct mucosal delivery of viral vectors can enhance both sys-
temic and secreted immune responses in mice who are primed
parenterally with DNA vaccines encoding the same target an-
tigens (11, 41). However, the performance of recombinant
bacteria, as either the priming or boosting component, in com-
bined immunization regimens including a DNA vaccine has
not been evaluated thoroughly.
Attenuated enteric bacteria, such as Salmonella enterica,
represent logical alternatives for boosting both systemic and
secreted immune responses in animals that were previously
primed with DNA vaccines encoding the same antigen. Atten-
uated Salmonella strains can colonize the intestinal mucosa
and efficiently target the carried heterologous antigens to the
gut-associated lymphoid tissue (GALT), leading to enhanced
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humoral and cellular mucosal immune responses (29). Atten-
uated S. enterica serovar Typhimurium strains can also tran-
siently invade the intestinal epithelia and proliferate at internal
tissues and organs, triggering effective systemic immune re-
sponses such as the production of antibodies and the activation
of other T-cell-dependent responses. Previous attempts to use
a recombinant Salmonella vaccine strain to prime or boost
immune responses in mice who were subjected to a vaccine
regimen including a DNA vaccine have been limited to the
administration of the bacterial strain via the parenteral route
and the evaluation of systemic responses to the encoded pro-
tein, a protective antigen derived from Mycobacterium tuber-
culosis (31). Based on these studies, the induced antibody re-
sponses elicited in mice subjected to the primer-booster
regimen did not show any significant improvement over those
attained by animals vaccinated with only with one vaccine type,
irrespective of the vaccine administration order (31).
Enterotoxigenic Escherichia coli (ETEC) is a common cause
of acute infantile diarrhea in developing countries and in trav-
elers who visit such areas (4). Colonization of the small intes-
tine, the first step in the establishment of the diarrheic disease,
is a major ETEC virulence-associated feature and is the target
of vaccines aiming for the generation of secreted immunoglob-
ulin A (IgA) responses that are able to block the attachment of
bacteria to intestinal epithelial cells (21). Colonization factor
antigen I (CFA/I) represents one of the best-studied fimbriae
expressed by human-derived ETEC strains and has a wide-
spread occurrence in areas of endemicity (14). Antibodies
binding to specific epitopes at the major structural fimbrial
subunit, the CfaB protein, have been shown to inhibit the
adhesive properties of CFA/I ETEC strains (5, 35). None-
theless, despite the magnitude of the disease burden in devel-
oping countries, no ETEC vaccine for human use has been
licensed, and this need therefore represents a priority for most
developing countries and for the World Health Organization
(36).
Members of our laboratory previously failed to induce se-
creted IgA responses in mice who were parenterally immu-
nized with DNA vaccines encoding the CFA/I fimbria struc-
tural subunit (1). However, the priming of animals with an
intramuscularly (i.m.) delivered DNA vaccine encoding the
CfaB subunit followed by oral boosting with a recombinant
S. enterica serovar Typhimurium vaccine strain expressing the
same antigen has been shown to enhance both systemic and
secreted antibody responses to the ETEC antigen (27). For this
work, we evaluated some properties of the immune responses
elicited in mice that were subjected to the DNA primer-Sal-
monella booster immunization regimen and evaluated aspects
that affected the systemic and secreted antibody responses to
the target antigen, both quantitatively and qualitatively. The
present results show that the combined immunization regimen
can also be an alternative for the development of vaccines
against enteric pathogens.
MATERIALS AND METHODS
Bacterial and mouse strains. The S. enterica serovar Typhimurium SL3261
strain, a nonreverting aromatic-dependent (aroA) vaccine strain, was kindly
supplied by B. A. Stocker (Stanford University). The ETEC 258909-3 strain
(CFA/I O128:H?, heat-stable enterotoxin/heat-labile enterotoxin) and its iso-
genic nonfimbriate derivative (258909-3 M) were gifts from A. M. Svennerholm
at the University of Gothenburg, Gothenburg, Sweden. The Salmonella HG3
strain was routinely cultivated in liquid Luria-Bertani (LB) broth at 37°C with
agitation, while the ETEC strains were grown on Casamino Acids-yeast extract
agar plates at 37°C, as previously described (1). Specific-pathogen-free isogenic
female BALB/c and DBA2 mice were supplied by the Isogenic Mouse Breeding
Facility of the Biomedical Sciences Institute at the University of Sa˜o Paulo. All
procedures were performed in accordance with the principles of the Brazilian
code for the use of laboratory animals and were approved by the Ethics Com-
mittee on Use of Laboratory Animals of the Biomedical Sciences Institute of the
University of Sa˜o Paulo.
Preparation of Salmonella-ETEC vaccine strain. The S. enterica serovar Ty-
phimurium SL3261 strain was transformed with plasmid pCFA-1, which encodes
the mature CfaB protein under control of the tac promoter (17). The recombi-
nant bivalent Salmonella-ETEC vaccine strain, named strain HG3, was obtained
after transformation with an F plasmid carrying a copy of the lacIq gene, which
allowed induction of the CfaB protein upon the addition of isopropyl--D-
thiogalactopyranoside (IPTG) to the growth medium (18). The HG3 strain was
cultivated at 37°C in LB broth in the presence of 0.5 M IPTG for 4 h, harvested
by centrifugation, washed once, suspended in phosphate-buffered saline (PBS) to
a final concentration of 2  1010 CFU/ml, and inoculated on the same day of
preparation. CfaB expression by the S. enterica serovar Typhimurium HG3 strain
was confirmed for each administered dose. When required, both the Salmonella
and ETEC strains were inactivated by suspension in 70% ethanol, an overnight
incubation at 4°C before washing, and a final suspension in sterile PBS.
Preparation of DNA vaccine. Plasmid pRECFA, kindly supplied by G. Cohen
(University of Pennsylvania), was derived from pRE4 (7) and encodes a hybrid
CfaB protein fused with the herpes simplex virus (HSV) type 1 glycoprotein D
(gD) under the control of a Rous sarcoma virus (RSV) promoter (1). pRECFA
and pRE4 were purified by equilibrium density centrifugation in a CsCl gradient,
which was repeated twice, and then were precipitated with ethanol and sus-
pended in PBS (1).
Immunization regimen and sample collection. Groups of five 4- to 6-week-old
female BALB/c mice were inoculated i.m. twice with 50 g of pRECFA or pRE4
at each hind limb tibialis anterior muscle (100 g/dose) at intervals of 2 weeks.
The standard immunization regimen employed two peroral (p.o.) boosting doses
with 1010 CFU of the HG3 strain, given 1 week apart, starting 2 weeks after the
last DNA immunization. The same procedure was repeated for experiments with
live or inactivated ETEC bacteria. For some experiments, the interval between
the last DNA dose and the first HG3 dose was increased up to 52 weeks. For
another set of experiments, the amount of priming DNA was reduced to 50, 10,
or 1 g per dose. To evaluate the role of mouse age on the induced antibody
responses, we vaccinated 7-day- to 52-week-old mice with the first DNA dose of
the standard immunization regimen. Control immunization groups were vacci-
nated with two i.m. doses of pRECFA, two p.o. doses of the HG3 strain, or two
priming i.m. doses of pRE4 followed by two p.o. doses of the HG3 strain. All
immunization experiments were repeated at least twice, except those based on
intervals of 16 and 52 weeks between the last priming DNA dose and the first
booster with the Salmonella HG3 strain. Two weeks after the last immunization
with the HG3 strain, the mice were bled by puncturing the retro-orbital plexus,
and feces were collected for one night. Individual blood samples were tested for
anti-CfaB antibody responses, pooled, and then stored at 20°C for further
testing. Fecal pellets were first freeze-dried and then were stored at 20°C.
Before testing, 15 pellets (approximate 0.6 g) were homogenized in 500 l of PBS
and centrifuged at 10,000  g for 10 min at 4°C. The supernatants were collected
for determinations of CfaB-specific IgA levels. Anti-CfaB total IgG, IgG1,
IgG2a, and IgA titers were determined by enzyme-linked immunosorbent assays
(ELISAs) with purified CFA/I fimbriae.
In vitro transfection of mammalian cells. BHK-21 cells were transfected with
either pRECFA or pRE4 by the use of Lipofectamine in Dulbecco’s modified
Eagle’s medium (Invitrogen) under conditions suggested by the manufacturer.
The cells were harvested 48 h after transfection, whole-cell extracts were sus-
pended in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer and boiled for 5 min, and the proteins were sorted by
SDS-PAGE followed by Western blotting.
SDS-PAGE and Western blotting. SDS-PAGE was performed according to
standard procedures in a Mini Protean II vertical electrophoresis unit (Bio-Rad).
The samples were boiled in an equal amount of sample buffer (0.625 M Tris [pH
6.8], 10% [vol/vol] glycerol, 2% [wt/vol] SDS, and 5% mercaptoethanol in dis-
tilled water) for 5 min and then applied to 15% (wt/vol) acrylamide gels. The gels
were run at 120 V, and the sorted proteins were transferred to nitrocellulose
sheets (0.45-m pore size; Sigma) at 200 mA for 1 h under previously described
buffer conditions (1). After an overnight block with 1% (wt/vol) bovine serum
albumin-PBS at 4°C, the sheets were incubated at room temperature for 1 h with
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MAb84, a CfaB-specific mouse monoclonal antibody (MAb) that is able to
recognize an unexposed linear epitope, followed by an additional 1-h incubation
with diluted (1:3,000) horseradish peroxidase-conjugated rabbit anti-mouse IgG
(Sigma). The membranes were developed by use of an ECL kit (Amersham) and
were exposed to Kodak-X Omat films for 1 min.
Detection of specific antibody responses. ELISAs were performed as previ-
ously described (1), with purified heat-denatured CFA/I fimbriae as the solid-
phase bound antigen. Briefly, 96-well MaxiSorp plates (Nunc) were coated with
purified heat-denatured CFA/I fimbriae (0.1 g/well), and after blocking, the
plates were incubated for 1 h with serially diluted mouse sera or fecal extracts.
After being washed, the plates were incubated with diluted (1:3,000) peroxidase-
conjugated rabbit anti-mouse IgG, IgA (Sigma), IgG1, or IgG2a (Southern
Biotechnologies) for an additional hour. The color reactions were made visible
by the use of O-phenylenediamine (0.4 mg/ml; Sigma) and H2O2. Absorbance
values were measured at 492 nm in a microtiter plate reader (LabSystem), and
end-point titers (IgG, IgG1, and IgG2a) were automatically calculated by the
Microcal Origin 6.0 Professional program as the reciprocal values of the last
dilutions with an optical density of 0.1. Fecal IgA results were expressed as A492
values of serially diluted fecal extracts. Background levels, as determined with
preimmunization serum pools, were deducted from the results obtained with the
different immunization groups. Determinations of the statistical significance of
the antibody titers were performed by use of the end-point titers (serum IgG) or
A492 values of the lowest tested dilution (IgA fecal extracts).
Detection of anti-CfaB ASC by enzyme-linked immunospot assay. Spleens
from five immunized BALB/c mice were removed, and single-cell suspensions
prepared in RPMI 1640 medium were supplemented with 5% fetal calf serum, 2
mM L-glutamine, 0.05% 2-mercaptoethanol, penicillin (100 U/ml), and strepto-
mycin (100 g/ml), as previously described (15). A similar procedure was applied
to obtain single-cell suspensions of five isolated Peyer’s patches (PP) and mes-
enteric lymph nodes (MLN) from each immunized mouse. Reactions were car-
ried out in Nunc Maxisorp 96-well plates coated overnight (4°C) with purified
CFA/I fimbriae (2 g/well) in 0.05 M carbonate-bicarbonate buffer, pH 9.6. The
plates were blocked with 1% gelatin in PBS at 37°C for 2 h. Titrated numbers of
cells from spleens, PP, or MLN (107 cells/ml) in RPMI medium with 2% fetal calf
serum were cultured for 6 h at 37°C in a 5% CO2 atmosphere. After being
washed, the plates were treated with goat anti-mouse IgG or goat anti-mouse
IgA conjugated with alkaline phosphatase (Sigma) at a final dilution of 1:3,000.
After an incubation for 2 h at 37°C, the plates were washed, and antibody-
secreting cells (ASC) were detected after the addition of molten agarose con-
taining 5-bromo-chloro-3-indolyl phosphate (Sigma) diluted in 2-amino 2-methyl
1-propanol (Merck). The experiment was based on duplicate plates for each
tested sample, and the total numbers of specific IgG- or IgA-producing ASC
were determined by counting the corresponding blue spots under a dissecting
microscope.
Detection of cytokines in culture supernatants. For in vitro cytokine measure-
ments, splenocytes isolated from five BALB/c mice were cultured in 24-well
tissue culture plates at a final concentration of 5 106 cells/ml in RPMI and then
were stimulated with purified CfaB protein (25 g). Supernatant fluids were
harvested after 24 or 72 h of incubation at 37°C in 5% CO2 and were assayed for
their interleukin-4 (IL-4) or gamma interferon (IFN-) content, respectively.
Cytokine assays were performed by two-site sandwich ELISAs using the follow-
ing MAbs: for IL-4, 11B11 (2 g/ml) and biotinylated BVD6-24G2 (2 g/ml);
and for IFN-, XMG 12 (2 g/ml) and biotinylated AN 18 (4 g/ml). The binding
of biotinylated MAbs was detected by use of a diluted (1:4,000) streptavidin-
biotinylated horseradish peroxidase complex (Sigma) and 2,2-azino-bis (3-eth-
ylbenz-thiazoline-6-sulfonic acid) substrate solution (Sigma) in 0.1 M citrate
buffer containing hydrogen peroxide. Samples were quantified by comparisons
with standard curves of recombinant mouse cytokines. The results are expressed
in nanograms of secreted cytokines per milliliter and are arithmetic means of
duplicate cultures  standard deviations.
Inhibition of ETEC adherence to Caco-2 cells and hemagglutination (IHA).
Caco-2 cells were maintained in Dulbecco’s modified Eagle’s medium supple-
mented with gentamicin (100 g/ml), kanamycin (50 g/ml), L-glutamine (2
mM), 100 M minimum essential medium nonessential amino acid solution
(Invitrogen), and 10% fetal calf serum in a humidified atmosphere containing
5% CO2 at 37°C. The in vitro inhibition of ETEC adherence to Caco-2 cell
monolayers was determined by the use of heat-inactivated sera (60°C for 1 h)
from nonimmune and immunized mice. For evaluations of the inhibitory action
of anti-CfaB antibodies, serum or fecal samples were incubated at a final dilution
of 1:3 with 107 ETEC bacteria for 1 h at 37°C before being added to Caco-2
cultures. After incorporation of the bacteria, the Caco-2 monolayers were kept at
37°C for 3 h. The cell monolayers were washed with PBS, fixed with methanol,
and stained with Giemsa solution to visualize the adherent bacteria by oil im-
mersion light microscopy. The number of Caco-2 cells with bound bacteria in a
set of 100 cells was determined for each tested antibody. IHA tests were per-
formed on glass plates with drops (10 l) of the ETEC 258909-3 strain at an
optical density at 600 nm of 0.15 incubated for 10 min with aliquots (10 l) of
twofold serial dilutions of serum pools or filtered fecal extracts harvested from
different mouse immunization groups. Aliquots (20 l) of a 3% suspension of
human group A erythrocytes that had been washed in PBS were added to the
treated bacterial samples and incubated at room temperature for 30 min in
humidified chambers. The results were evaluated by visual inspection, and the
maximal dilutions that were able to inhibit the hemagglutination reaction were
noted. D-Mannose was added at a concentration of 1% (wt/vol) to the dilution
buffer (PBS) for both tests to avoid binding mediated by type 1 fimbriae. The test
was repeated independently at least three times. The assay specificities were
confirmed with tests performed with the CFA/I-negative ETEC 258909-3 M
strain. Serum samples from animals subjected to the primer-booster regimen
were diluted with PBS to titers similar to those harvested from mice immunized
only with pRECFA to allow a more precise comparison of the antiadhesive
properties of the tested antibodies.
Protective role of anti-CfaB antibodies in murine neonatal challenge model. A
neonatal ETEC challenge model (10) was adapted for the human-derived
258909-3 strain. Briefly, bacterial cells cultivated on CFA plates for 18 h at 37°C
were gently suspended in PBS to a final concentration of 109 CFU/ml. Bacterial
cell aliquots containing 2  107 CFU were mixed with anti-CfaB serum samples
at a final dilution of 1:25 or 1:50. The mixtures were incubated at room temper-
ature for 1 h and then directly inoculated, in 200-l aliquots, into the stomachs
of neonate mice within the first 48 h of birth by use of a syringe for insulin
administration (12.7 by 0.33 mm needle; BD). The inoculated pups were re-
turned to their respective dams and kept under observation for 1 week. All
deaths registered between 24 h and 6 days after the challenge were considered
for mortality rate determination. Control test groups were inoculated with the
258909-3 strain, which had previously been incubated with a nonimmune serum
pool or PBS.
Statistical analyses. Antibody titers and cytokine production were compared
by use of the Student t test, and significance was assessed at P values of 	0.05
throughout the study.
RESULTS
Parenteral priming with DNA and oral boosting with a re-
combinant Salmonella strain confers synergic systemic (serum
IgG) and secreted (fecal IgA) antibody responses to ETEC
CFA/I fimbriae. The vaccine regimen used for this study was
based on the i.m. delivery of a DNA vaccine, pRECFA, en-
coding the CfaB subunit genetically fused to the HSV gD1
protein under control of the RSV early promoter (Fig. 1),
followed by oral administration of the recombinant S. enterica
serovar Typhimurium HG3 strain, which intracellularly ex-
presses the mature nonfused form of the CfaB subunit (Fig. 1).
BALB/c mice who were primed with two doses of pRECFA
and then received boosters 2 weeks later consisting of two oral
doses of the CFA/I-expressing HG3 strain developed serum
IgG responses to the commonly encoded CfaB subunit which
could not be attained in mice who were immunized with only
one vaccine type (Fig. 2). Mice that were immunized with the
primer-booster regimen developed CfaB-specific IgG levels
which were at least twofold higher than the levels attained in
mice that were immunized with two or more i.m. doses of
pRECFA (average reverse titers of 8,280 220 for the primer-
booster regimen and 4,268  168 for immunization with
pRECFA only). The difference between the anti-CfaB serum
IgG levels in mice subjected to the primer-booster vaccine
procedure and those in mice who were immunized with two
doses of the HG3 strain only was even higher (up to 20-fold),
which could be attributed to the reduced immunogenicity of
this particular Salmonella vaccine strain when delivered via the
oral route (17) (Fig. 2A). Mice that were primed with the
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plasmid vector without the cloned cfaB gene (pRE4) and then
boosted with the HG3 strain did not mount any enhanced
systemic anti-CfaB serum antibody responses. More relevantly,
mice subjected to the priming-boosting immunization regimen
elicited enhanced CfaB-specific secreted IgA responses in fe-
ces compared to animals who were immunized with pRECFA
or the HG3 strain only or who were primed with pRE4 and
boosted with the HG3 strain (Fig. 2B). Therefore, under our
assay conditions, parenteral administration of the DNA vac-
cine was able to prime not only systemic but also secreted
antibody responses to the encoded antigen, as demonstrated
with mice who received oral boosters with the recombinant
Salmonella strain. Curiously, an inversion of the immunization
regimen, i.e., priming with the orally delivered HG3 strain
followed by i.m. boosting with pRECFA, did not result in any
synergy of the induced anti-CfaB antibody responses, either in
the serum (IgG) or feces (IgA). Indeed, oral priming with the
recombinant HG3 strain caused a reproducible antagonistic
effect on the induced anti-CfaB antibody responses compared
to those in mice who were vaccinated with only the DNA vac-
cine (Fig. 2A).
The impact of the primer-booster immunization regimen on
the activation of enhanced fecal anti-CfaB IgA responses was
further confirmed by the detection of ASC in PP and MLN by
an ELISPOT assay. As indicated in Table 1, CfaB-specific
IgA-secreting cells in PP and MLN were detected only in mice
who were subjected to the DNA primer-Salmonella booster
regimen, while no CfaB-specfic ASC were detected in mice
who were vaccinated with pRECFA or the HG3 strain only or
who were primed with pRE4 and boosted with the HG3 strain.
The number of CfaB-specific ASC in spleens of animals sub-
jected to the primer-booster regimen was also higher (13-fold
increase [P 	 0.05]) than that in spleens of mice who were vac-
cinated only with pRECFA (Table 1). Taken together, these re-
sults indicate that parenteral priming with a DNA vaccine can
indeed prime both systemic and secreted antibody responses in
mice receiving oral boosters with a recombinant Salmonella
strain encoding the same antigen. The available evidence also
indicates that under our testing conditions, the order of the
priming and boosting doses is essential for the observed syn-
ergic effect on the induced antibody responses. Once the ef-
fects of the immunization regimen on both systemic and secret-
ed antibody responses were established, additional experiments
were performed in order to evaluate some of the conditions
affecting the immunogenicity of the primer-booster regimen.
Factors affecting the systemic and secreted antibody re-
sponses induced by the primer-booster immunization regimen.
The ability of the DNA priming-Salmonella boosting immuni-
zation regimen to elicit enhanced secreted and systemic anti-
body responses to the CfaB antigen in mice who were sub-
jected to the regimen was evaluated according to four different
parameters: (i) the nature of the bacterial vector used to boost
FIG. 1. Schematic representation of CfaB-encoding plasmids and in vitro expression of the encoded peptides. (A) The pRECFA vaccine was
obtained after cloning of the PCR-amplified cfaB gene into the pRE4 vector after PvuII-ApaI double digestion of both the fragment and the
plasmid (1). The encoded CfaB protein was expressed as an in-frame sandwich fusion with the HSV-1 gD protein under control of the RSV late
promoter. (B) The pCFA-1 plasmid was generated after cloning of a PCR-generated DNA fragment encoding the mature portion (without the
signal peptide) of the structural subunit of the CFA/I fimbriae into the SmaI-digested pKK223-3 bacterial expression vector (17, 18). The peptide
expressed by transformed Salmonella strains accumulated as an intracellular protein that was unable to form native CFA/I fimbriae. (C) Immuno-
logical detection of CfaB expression in whole-cell extracts in a Western blot developed with a specific monoclonal antibody (MAb 84). Samples: 1,
purified CFA/I fimbriae isolated from an ETEC strain; 2, BHK-21 whole-cell extract; 3, pRE4-transfected BHK-21 cells; 4, pRECFA-transfected
BHK-21 cells; 5, S. enterica serovar Typhimurium SL3261 strain; 6, S. enterica serovar Typhimurium HG3 strain cultivated without inducer (IPTG); 7,
S. enterica serovar Typhimurium HG3 cultivated for 4 h in the presence of 0.5 M IPTG. Each lane was loaded with approximately 25 g of total protein.
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the immune responses, (ii) the age of the animals at the time
that the vaccine regimen was begun, (iii) the interval between
the priming and boosting immunizations, and (iv) the amount
of priming DNA vaccine. To investigate the role of the bacte-
rial strain on the induction of antibody responses, we tested the
live or ethanol-inactivated CfaB-expressing HG3 strain or a
CFA/I ETEC strain as boosting antigens in mice who were
previously primed with the DNA vaccine. Mice who received
oral boosters with the live or inactivated Salmonella HG3
strain or with the live CFA/I ETEC strain developed statis-
tically significantly (P 	 0.05) different systemic anti-CfaB IgG
titers from those in mice who were immunized only with
pRECFA, although mice who were boosted with the live HG3
strain consistently yielded higher anti-CfaB serum IgG re-
sponses. Regarding the fecal IgA responses, boosting with live
HG3 cells was the only stimulus that was able to elicit statis-
tically significant differences in the anti-CfaB IgA levels de-
tected among mice subjected to the primer-booster immuni-
zation regimen (see Fig. 4A).
The ability to activate both systemic and secreted antibody
responses to the CfaB antigen was age dependent both for
animals subjected to the primer-booster regimen and for those
who were vaccinated i.m. with pRECFA. As shown in Fig. 3B,
mice who were first immunized with pRECFA 1 week after
birth developed higher serum IgG responses than 4- or 52-
week-old animals subjected to the primer-booster regimen. On
the other hand, 4-week-old mice developed the highest anti-
CfaB IgA levels in fecal extracts compared to the other mouse
groups that were subjected to the primer-booster regimen (Fig.
4B). However, regardless of age, all mouse groups subjected to
the primer-booster regimen developed higher anti-CfaB serum
IgG or fecal IgA levels than age-matched groups immunized
only with pRECFA or with the HG3 strain, respectively (Fig.
3B and 4B; also data not shown).
We also determined the optimal interval between parenteral
priming with pRECFA and the first booster dose with the
recombinant Salmonella HG3 strain for the specific systemic
and secreted antibody responses to the encoded antigen. An
interval of 8 weeks between the second pRECFA dose and the
first Salmonella booster resulted in a maximal synergistic effect
on the systemic anti-CfaB IgG responses, which were approx-
imately 30-fold higher than the IgG levels attained in mice who
were immunized with only pRECFA and 10-fold higher than
those detected in mice subjected to a regimen with a 2-week
interval (Fig. 3C). On the other hand, maximal anti-CfaB fecal
FIG. 2. Systemic (serum IgG) and secreted (fecal IgA) CfaB-spe-
cific antibody responses elicited in BALB/c mice subjected to different
immunization regimens. Serum IgG (A) and fecal IgA (B) anti-CfaB
responses were measured in ELISA plates coated with heat-denatured
CfaB protein purified from a CFA/I ETEC strain. Sera were col-
lected from the following immunization groups (at least five animals
per group): pRECFA (Œ), mice immunized with two i.m. doses of
pRECFA (100 g/dose); HG3 (■), mice immunized with two p.o.
doses of IPTG-induced S. enterica serovar Typhimurium HG3 (1010
CFU/dose); pRE4HG3 (), mice immunized with two i.m. doses of
the empty vector pRE4 (100 g/dose) followed by two p.o. doses of the
HG3 strain; pRECFA  HG3 (}), the complete primer-booster im-
munization regimen, with mice immunized with two i.m. doses of
pRECFA followed by two p.o. doses of the HG3 strain; HG3 
pRECFA (), inverse primer-booster immunization regimen consist-
ing of two p.o. doses of the HG3 strain followed by two i.m. pRECFA
doses. Data corresponding to three determinations are presented as
means  standard errors (SE) of the titers (serum IgG) or of absor-
bance values at 492 nm of the reactions with diluted fecal extracts
(fecal IgA). All values were deducted from the background values
obtained with nonimmune sera. All bars marked with an asterisk show
statistically significantly different values (P 	 0.05) compared to the
results of the pRECFA (serum IgG)- or HG3 (fecal IgA)-vaccinated
mouse group.
TABLE 1. Detection of CfaB-specific ASC by ELISPOT assays
with mice subjected to different immunization regimens
Vaccination
regimena
No. of CfaB-specific ASC/106 splenocytesb
Spleen PP MLN
Nonimmunized 0 0 0
pRECFA 10  0.4 0 0
HG3 0 0 0
pRE4  HG3 0 0 0
pRECFA  HG3 130  4* 7  0* 20  0.8*
a Vaccination regimens: non-immunized mice; pRECFA, mice immunized
with two i.m. doses of pRECFA (100 g/dose); HG3, mice immunized with two
p.o. doses (1010 CFU/dose) of the HG3 strain; pRE4  HG3, mice immunized
with two doses of pRE4 followed 2 weeks later by two booster doses with the
HG3 strain; pRECFA  HG3, mice subjected to the standard primer-booster
immunization regimen, with a 2-week interval between the priming and boosting
immunizations.
b CfaB-specific ASC were detected after incubation of the cells with alkaline
phosphatase-conjugated goat anti-mouse IgG (spleen) or goat anti-mouse IgA
(Peyer’s patches and mesenteric lymph nodes). All cells were harvested 2 weeks
after the last immunization dose either from groups that were vaccinated with a
single vaccine type or from groups that were subjected to primer-booster regi-
mens. The results are based on one determination and are expressed as means 
SE. *, statistically significant (P	 0.05) differences compared with corresponding
results for mouse groups immunized with pRECFA.
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IgA responses were detected in animals who received boosters
4 weeks after the second DNA immunization, and these were
at least threefold higher than the anti-CfaB IgA levels attained
in mice subjected to an immunization regimen with an interval
of 2, 8, or 16 weeks between the priming doses and the first
booster with Salmonella (Fig. 4C). It should be noted that the
synergic effects of the primer-booster immunization regimen
on the induced anti-CfaB serum IgG responses were detected
even for an interval of 52 weeks between priming and the first
booster dose, even though the final titer values were much
lower than those attained in animals who were vaccinated with
shorter intervals between the priming and boosting doses.
Mice who were primed with two doses consisting of 50 g
(each) of pRECFA mounted anti-CfaB serum IgG and fecal
IgA responses similar to those by animals who were primed
with 100 g of DNA. Further reductions in the amount of
DNA (10 or 1 g) used in the priming doses significantly re-
duced both the systemic and secreted CfaB-specific antibody
responses elicited in mice subjected to the primer-booster im-
munization regimen (Fig. 3D and 4D).
Mice subjected to the primer-booster immunization regi-
men developed a prevailing Th1-type cell response pattern. An
analysis of the serum IgG subclass responses revealed that
mice subjected to the primer-booster immunization regimen
developed a predominant IgG2a response, with an IgG1/IgG2a
ratio of 0.29. Mice who were vaccinated with pRECFA (IgG1/
IgG2a 
 0.18) or the HG3 strain (IgG1/IgG2a 
 0.14) only or
who were primed with pRE4 and boosted with the HG3 strain
(IgG1/IgG2a 
 0.15) developed similar IgG2a-dominated se-
rum antibody responses (Fig. 5A). To further confirm the
involvement of Th1-type cells on the observed antibody re-
sponses, we measured the amounts of IFN- and IL-4 secreted
by CD4 T cells present in spleen homogenates harvested
from mice who were subjected to different immunization reg-
FIG. 3. Factors affecting serum anti-CfaB IgG responses elicited in mice subjected to the DNA priming-Salmonella boosting immunization
regimen. (A) Nature of the bacterial carrier given to mice primed with pRECFA. Mice were boosted p.o. with live (HG3) or ethanol-inactivated
(HG3 k) S. enterica serovar Typhimurium HG3 or with live (ETEC) or ethanol-inactivated (ETEC k) ETEC 258909-3. As a control, the mean
CfaB-specific serum IgG titer of mice immunized with two doses of pRECFA is indicated (pRECFA). (B) Age-dependent CfaB-specific antibody
responses elicited in mice who were first immunized with pRECFA at the age of 1 week (young), 6 weeks (adult), or 52 weeks (old). Mice were
immunized with two i.m. doses (100 g/dose) of pRECFA (black bars) or with the complete primer-booster regimen (white bars). (C) Interval
between the last priming dose with pRECFA and the first oral booster with the CfaB-expressing HG3 strain. CfaB-specific antibody levels detected
for mouse groups subjected to the primer-booster regimens with intervals of 2, 4, 8, 16, and 52 weeks between the priming and boosting doses are
indicated by white bars. As controls, anti-CfaB antibody titers detected in sera of mice who were vaccinated only with two doses of pRECFA and
then bled at the same periods as those subjected to the complete primer-booster regimen are indicated by black bars. (D) Amount of DNA required
to prime CfaB-specific antibody responses in mice receiving oral boosters with the HG3 strain. The amount of DNA inoculated in each dose is
indicated (100, 50, 10, or 1 g). Data corresponding to one representative determination are presented as means SE of the titers. All bars marked
with an asterisk show statistically significantly different values (P	 0.05) compared to the results obtained with pRECFA-vaccinated mouse groups
that were subjected to the same testing conditions.
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imens and stimulated with purified CfaB protein. As expected,
enhanced IFN- levels were detected in the culture superna-
tants of splenocytes isolated from mice who were subjected to
the primer-booster immunization regimen, while IL-4 was not
detectable under our assay conditions (Fig. 5B). Taken togeth-
er, these results indicate that mice subjected to the pRECFA
primer-Salmonella booster immunization regimen developed
prevailing Th1-type cell responses.
Recognition of native CFA/I fimbriae by antibodies raised in
mice subjected to the primer-booster immunization regimen.
To efficiently inhibit the binding of CFA/I ETEC strains,
anti-CfaB antibodies raised in vaccinated mice must recognize
epitopes located on the surfaces of intact CFA/I fimbriae and
must block binding to host cell glycolipid receptors (35). To
evaluate the protective potential of the anti-CfaB serum pools
collected from mice who were subjected to different immuni-
zation regimens, we used human type A red blood cells in IHA
tests and measured the ability of sera to block the binding of
CFA/I ETEC bacteria to in vitro-cultured Caco-2 cells. As
shown in Table 2 and Fig. 6, serum pools from mice who were
immunized only with pRECFA or with the HG3 strain did not
inhibit hemagglutination or binding of the CFA/I ETEC
258909-3 strain to Caco-2 cells. On the other hand, serum
samples harvested from mice who were subjected to the com-
bined DNA primer-Salmonella booster regimen promoted
complete inhibition of the binding properties of the CFA/I
fimbriae expressed by live ETEC strains, even after dilution to
titers similar to those derived from pRECFA-vaccinated mice.
FIG. 4. Factors affecting secreted anti-CfaB fecal IgA responses elicited in mice subjected to the DNA priming-Salmonella boosting immuni-
zation regimen. (A) Nature of the bacterial carrier given to pRECFA-primed mice. Mice were boosted p.o. with live (■, pRECFA  HG3) or
ethanol-inactivated (, pRECFA  HG3 k) S. enterica serovar Typhimurium HG3 or with live (}, pRECFA  ETEC) or ethanol-inactivated (,
pRECFA  ETEC k) ETEC 258909-3. As a control, CfaB-specific fecal IgA titers for a mouse group that was immunized with two doses of
pRECFA are indicated (Œ, pRECFA). (B) Age-dependent CfaB-specific antibody responses elicited in mice who were first immunized with
pRECFA at an age of 1 week (Œ, young), 6 weeks (■, adult), or 52 weeks (}, old) and then boosted with two doses of the HG3 strain given 2
weeks apart (pRECFA  HG3). As controls, age-matched mouse groups (pRECFA) were immunized with two i.m. doses (100 g/dose) of
pRECFA, as indicated by the open symbols. (C) Interval between the last priming dose with pRECFA and the first oral booster with the
CfaB-expressing HG3 strain. CfaB-specific fecal IgA levels detected in mouse groups that were subjected to intervals of 2 (Œ), 4 (■), 8 (), 16
(}), and 52 () weeks are indicated. (D) Amount of DNA required to prime CfaB-specific fecal IgA responses in mice receiving oral boosters with
the HG3 strain. The amount of DNA inoculated in each dose was 100 g (Œ), 50 g (■), 10 g (), or 1 g (}). Experiments were performed
with pools of fecal extract collected from different immunization groups. The results shown are based on a representative experiment and are
expressed as A492 values for twofold serial dilutions. Statistically significant results (P  0.05) with regard to mouse groups primed with pRE4 and
boosted with the HG3 strain at the lowest tested dilutions were obtained for the following groups: A, pRECFA  HG3; B, pRECFA  HG3 adult
and pRECFA  HG3 young; C, all groups except the one with an interval of 52 weeks; D, mouse groups that were immunized with 100 or 50 g
of pRECFA.
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Similarly, only anti-CfaB antibodies present in fecal extracts of
mice subjected to the primer-booster regimen were able to
inhibit the adhesive properties of the CFA/I fimbriae (Table
2). These results indicate that the primer-booster regimen also
enhanced the specificity of antibodies to epitopes involved in
the binding properties of the CFA/I fimbriae.
Antibodies raised in mice subjected to the primer-booster
immunization regimen confer protection to newborn mice
challenged with a CFA/I ETEC strain. As a step toward an
evaluation of the protective role of antibodies raised in mice
who were subjected to the primer-booster immunization
regimen, we adapted a previously described newborn mouse
challenge assay (10) for use with the human-derived ETEC
258909-3 strain and the DBA2 mouse lineage. Initial experi-
ments allowed us to show that intrastomach inoculation of 107
CFU of the ETEC strain resulted in 100% mortality of DBA2
neonate mice within 6 days after the challenge. Moreover, a
previous incubation of the bacteria with antibodies raised in
mice who were immunized with purified CFA/I fimbriae re-
duced the observed neonate mortality to values similar to those
attained with a nonadherent and nontoxigenic isogenic ETEC
strain (data not shown). As shown in Table 3, the mortality rate
of DBA2 neonate mice inoculated with the ETEC 258909-3
strain which had previously been incubated with a serum pool
from mice who were subjected to the vaccine regimen was
reduced to 18% of that for mice inoculated with bacteria that
were incubated with nonimmune sera. Serum samples har-
vested from mice who were immunized with two doses of
pRECFA or two doses of the HG3 strain were not able to
confer any protection to the challenged neonates (Table 3). As
a positive control, a pooled serum sample harvested from mice
who were immunized with purified CFA/I fimbria preparations
reduced the mortality frequency to 25% of that caused by an
ETEC strain that was treated with nonimmune sera. These
results further demonstrate that antibodies raised in mice sub-
jected to the combined vaccine regimen can recognize and
neutralize the adhesive properties of the CFA/I fimbriae.
DISCUSSION
Vaccine strategies based on priming with DNA followed by
boosting with recombinant viruses have been shown to induce
unprecedented levels of specific immunity and, in same cases,
protection from diseases that are not yet preventable by vac-
cines (2, 33, 34, 37, 40). Most of these reports were based on
FIG. 5. Activation of Th1-type responses in mice subjected to the
primer-booster immunization regimen. (A) Determination of anti-
CfaB IgG1 (white bars) and IgG2a (black bars) subclasses in serum
samples collected from mice who were immunized only with pRECFA
(pRECFA) or the CfaB-expressing HG3 strain (HG3), primed with
pRE4 and boosted with the HG3 strain (pRE4  HG3), or subjected
to the complete primer-booster regimen (pRECFA  HG3). (B) De-
termination of IFN- (black bars) and IL-4 (white bars) production in
spleen homogenates harvested from mice who were immunized only
with pRECFA (pRECFA) or the CfaB-expressing HG3 strain (HG3),
primed with pRE4 and boosted with the HG3 strain (pRE4  HG3),
or subjected to the complete primer-booster regimen (pRECFA 
HG3). Cell cultures were stimulated with 25 g of purified heat-
denatured CFA/I fimbriae/ml. IgG subclass (two determinations) and
cytokine (one determination) detection values are represented by end-
point reverse titers  SE and mean nanograms per milliliter  SE,
respectively. , statistically different values (P 	 0.05) compared to
results obtained with pRECFA-vaccinated mouse groups.
TABLE 2. Antiadhesive properties of serum pools harvested from
mice subjected to different regimens on live CFA/I ETEC bacteria,
as evaluated by the ability to inhibit CFA/I-mediated binding
to human erythrocytes (IHA) and Caco-2 cells
Vaccination
regimena
IHA resultb Caco-2 cells with
bound bacteria
(%)cSerum Fecal extract
Nonimmunized — — 92
pRECFA — — 90
HG3 1:4 1:4 88
pRE4  HG3 1:4 1:4 87
pRECFA  HG3 1:512 1:16 4*
a Serum pools were from mice subjected to the following immunization pro-
tocols: nonimmunized; pRECFA, mice immunized with two i.m. doses (100
g/dose) of pRECFA (titer of 4,268); HG3, mice immunized with two p.o. doses
of the HG3 strain (1010 CFU/dose) (titer of 305); pRE4  HG3, mice immu-
nized with two doses of pRE4 followed 2 weeks later by two booster doses with
the HG3 strain (titer of 420); pRECFA  HG3, mice subjected to the primer-
booster regimen, with a 2-week interval between the priming and boosting
immunizations (diluted in PBS to a final titer of 4,500).
b CFA/I-specific antiadhesive potencies were measured by IHA with human
group A red blood cells and the ETEC 258909-3 strain. Results are maximal
dilutions of serum or fecal extract samples that yielded visible inhibition of the
hemagglutination reactions. —, no visible reaction.
c The inhibition of adhesion of the ETEC 258909-3 strain to in vitro-cultivated
Caco-2 cell monolayers was also measured. The results are expressed as per-
centages of Caco-2 cells with at least one attached bacterium visible under an
optical microscope. All serum pools were used at a final dilution of 1:3 in
D-mannose-containing PBS. Data were based on the total number of cells
counted in two independent determinations. *, statistically different value (P 	
0.05) compared to results obtained with serum samples from other vaccinated
mouse groups.
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the parenteral administration of both priming and boosting
immunization, leading to the activation of systemic immune
responses, such as cytotoxic CD8 T cells (37, 40). In this
work, we reported the synergic induction of both serum and
intestinal antibody responses in mice subjected to a primer-
booster regimen based on parenteral priming with a DNA
vaccine and oral boosting with a recombinant Salmonella vac-
cine strain encoding the same heterologous antigen derived
from an enteric bacterial pathogen, the structural subunit of
the ETEC CFA/I fimbriae. A positive impact of the primer-
booster vaccine strategy was also noted on the ability of anti-
bodies to neutralize the binding properties of the CFA/I
fimbriae. Although a previous report has described a DNA
priming-Salmonella boosting immunization regimen based
on parenteral administration of the recombinant Salmonella
strain (31), as far as we know, the present report is the first one
to describe that oral administration of a Salmonella vaccine
strain can both quantitatively and qualitatively improve the
induced antibody responses targeting the encoded heterolo-
gous antigen. Based on this evidence, the proposed primer-
booster regimen can be considered an alternative for the de-
FIG. 6. Inhibition of binding properties of CFA/I fimbriae by serum samples collected from mice subjected to different immunization regimens.
The CFA/I ETEC 258990-3 strain was incubated with different serum samples for 1 h at 37°C, at a final dilution of 1:3, before being added to
Caco-2 cell cultures. The inhibition of bacterial binding was evaluated by assays using serum pools from nonimmunized mice (A), serum pools from
mice who were immunized with two i.m. pRECFA doses (titer of 4,268) (B), serum pools from mice who were immunized with two p.o. doses of
the HG3 strain (reverse titer of 305) (C), or PBS-diluted serum pools from mice subjected to the pRECFA priming-HG3 strain boosting
immunization regimen with a two-week interval between the priming and boosting doses (titer of 4,500) (D). Magnification, 2,000. The
experiment was repeated twice with the same observed results.
TABLE 3. Mortality rates of DBA2 neonate mice challenged with
the ETEC 258909 strain, which had been incubated with serum
pools from mice subjected to different immunization regimens
Serum samplea Anti-CfaBtiterb
No. of deaths/no.
of inoculated
mice (%)c
Nonimmunized 8/8 (100)
pRECFA 4,268 12/12 (100)
pRE4  HG3 420 10/10 (100)
pRECFA  HG3 4w 10,663 2/11 (18)*
CFA/I fimbriae 14,753 2/8 (25)*
a Tested serum samples were as follows: nonimmunized mice; pRECFA, mice
immunized with two i.m. pRECFA doses; HG3, mice vaccinated with two p.o.
doses of the HG3 strain; pRE4HG3, mice immunized with two doses of pRE4
followed 2 weeks later by two booster doses with the HG3 strain; pRECFA 
HG3 4w, mice subjected to the primer-booster regimen, with a 4-week interval
between the last DNA dose and the first Salmonella booster; CFA/I, mice
vaccinated with three i.p. doses (10 g each) of purified CFA/I fimbriae.
b Titers of the tested serum samples, as determined for IgG ELISA plates
coated with denatured CFA/I fimbriae.
c Mortality rates of DBA2 neonate mice after challenge with 2  107 CFU of
the ETEC 258909 strain, which was previously incubated for 1 h with the tested
serum samples. Serum samples were tested at a final dilution of 1:25 (HG3,
nonimmune, and pRECFA  HG3 4w) or 1:50 (CFA/I). *, statistically different
value (P 	 0.05) compared with the results obtained with serum samples from
mice immunized with pRECFA.
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velopment of vaccines against noninvasive enteric bacteria,
such as ETEC, as well as nonenteric pathogens.
The sequential parenteral priming with a DNA vaccine and
oral boosting with a recombinant Salmonella strain were shown
to comprise the most adequate regimen for enhancing anti-
body responses in both sera and intestinal mucosa of vacci-
nated mice. Inverting the vaccine administration order (oral
priming with Salmonella followed by i.m. boosting with DNA)
resulted in an apparent antagonistic effect on the induced
antibody responses, causing a reduction in the specific anti-
body levels among vaccinated animals. The reduced immuno-
genicity of the inverted vaccine regimen may be associated with
the induction of oral tolerance in vaccinated animals due to
repeated exposure to the antigen via the oral route, resulting in
subsequent suppression of the parenterally expressed antigen.
Opposite results were reported for a similar primer-booster
immunization regimen based on a recombinant vaccinia virus
vector, which elicited enhanced immune responses in mice
primed via the nasal route and boosted later with a DNA
encoding the same heterologous antigen (11). The distinct
nature of the vectors and the diverse administration sites most
probably explain the contrasting behaviors of the bacterial and
virus vectors used for priming immune responses in mice who
are subsequently boosted with DNA vaccines. Recombinant
Salmonella strains can more efficiently target the afferent sites
of the GALT, while recombinant poxviruses are clearly more
appropriate for priming immune responses when delivered via
the respiratory tract. Moreover, the intranasal environment
represents a more sensitive and less tolerance-prone mucosal
site than the intestinal lumen (32).
The nature of the oral booster antigen had a significant
impact on the induced systemic and, more relevantly, secreted
antibody responses among DNA-primed Salmonella-boosted
mice. Although enhanced serum anti-CfaB IgG responses were
detected in mice who received boosters with inactivated HG3
or live CFA/I ETEC bacteria, live recombinant Salmonella
reproducibly activated better secreted antibody responses in
mice subjected to the primer-booster regimen, which probably
reflects the ability of live Salmonella to efficiently target gut
mucosa afferent sites, invade, and multiply into deeper tissues
and organs (20). As expected, the ages of the animals at the
beginning of the immunization regimen had a profound effect
on the magnitude of the elicited secreted and systemic anti-
body responses. Mice who were immunized at earlier ages
systematically showed stronger antibody responses to the
encoded antigen than older individuals. Interestingly, while
young animals could mount enhanced serum IgG responses
when they were primed 7 days after birth, the synergic effect of
the primer-booster regimen on the mucosal immune responses
was better detected among animals who were 4 weeks old,
which suggested a delay in GALT maturation. An obvious
point was the fact that, irrespective of the ages of the mice and
the magnitudes of the antibody responses, all animals sub-
jected to the primer-booster regimen developed enhanced an-
tigen-specific antibody responses compared to age-matched
mice who were vaccinated only with the DNA vaccine. These
results indicate that the primer-booster vaccine regimen can be
active on individuals at early and late ages, which is a partic-
ularly relevant feature for vaccines designed for ETEC as well
as for other enteric pathogens, which inflict higher morbidity
and mortality rates among individuals at extreme ages (4).
Our results indicated that the administration of 50 g of
DNA/dose was enough to efficiently prime both systemic and
mucosal antibody responses to the commonly encoded antigen
among mice subjected to the primer-booster regimen, repre-
senting a significant economy of the amount of DNA required
for optimal immune responses. The interval between the two
priming DNA doses and the first oral booster dose with the
recombinant Salmonella strain was the most relevant parame-
ter affecting the antibody-inducing properties of the priming-
boosting immunization regimen. Mice who received the booster
8 weeks after the last DNA dose expressed maximal anti-CfaB
serum IgG titers which were at least 1 order of magnitude
higher than those detected in animals subjected to the stan-
dard regimen based on an interval of 2 weeks between priming
and boosting. Similar results were observed for the CfaB-spe-
cific fecal IgA responses, but with an optimal interval of 4
weeks between the priming and boosting immunizations. The
different optimal periods for the development of maximized
antibody responses in both the systemic and intestinal environ-
ments point to the differences in the kinetics of antigen pro-
cessing and stimulation of afferent cells in the two compart-
ments. Moreover, such results suggest that the optimal vaccine
regimen should take into account the type of antibody re-
sponse to be preferentially activated for an ideal protective
immunological state. Although they had different magnitudes,
the enhancements of the serum IgG responses promoted by
the primer-booster regimen could be detected for all tested
mice groups compared to control groups that were immu-
nized only with the DNA vaccine. Such evidence suggests
that pRECFA-primed animals develop long-term memory
responses that are able to trigger specific antibody responses
once boosted with live recombinant Salmonella strains. In prin-
ciple, for natives living in zones of endemicity, parenteral prim-
ing with an anti-ETEC DNA vaccine would elicit immunolog-
ical memory, leading to enhanced antifimbria responses after
later exposures with the locally prevailing ETEC strains, while
tourists could have the alternative to improve their protective
immunological status after the administration of an oral vac-
cine before traveling to areas of endemicity.
An analysis of the cellular basis of the responses elicited in
mice subjected to the primer-booster regimen emphasized the
role of CD4 Th1 cells on the induced immune responses. No
significant change on the Th cell stimulation pattern could be
detected between animals subjected to the primer-booster reg-
imen and those immunized with only one vaccine type, as
demonstrated both by the IgG1/IgG2a ratios and by the cyto-
kines produced by CFA/I-stimulated splenocytes. The activa-
tion of secreted IgA responses with the concomitant triggering
of a prevailing Th1 response, characterized by the secretion of
IFN- and a lack of detectable IL-4 production by activated
lymphocytes, may be explained by the presence of alternate
IgA-inducing pathways mediated by cytokines such as IL-10
which are stimulated upon oral immunization with Salmonella
vaccine strains (39). These observations also indicated that
changes in the expression levels of anti-CfaB antibodies raised
in mice subjected to the primer-booster regimen did not reflect
the differential activation of T helper lymphocyte subsets.
The ability to bind and block the adhesive properties of
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bacterial fimbriae is an essential feature of a protective anti-
body response aiming for the control of an enteroadhesive
pathogen such as ETEC. In contrast to the case for serum
samples collected from mice who were vaccinated only with
pRECFA or with two doses of the HG3 strain, serum and fecal
antibodies raised in mice subjected to the primer-booster reg-
imen could bind and neutralize the adhesive properties of a
CFA/I-expressing ETEC strain, as demonstrated by their
abilities to prevent adhesion to in vitro-cultured Caco-2 cells
and to inhibit hemagglutination. The expression of the
CfaB subunit genetically fused to the HSV-1 gD protein by
pRECFA-transfected cells resulted in the loss of conforma-
tional epitopes on the surfaces of intact CFA/I fimbriae, which
are important for the generation of neutralizing antibodies (1).
Thus, besides the inability to actively secrete IgA responses,
antibodies raised in mice who were immunized with parenter-
ally delivered DNA vaccines are usually affected by a loss of
the epitope specificity required for the adequate recognition
of native bacterial antigens. The recovery of the neutralizing
properties of the induced antibodies indicates that the primer-
booster regimen both quantitatively and qualitatively improved
the antibody responses elicited by the DNA vaccine and sug-
gests that the recombinant Salmonella strain played a major
role in the affinity maturation of established systemic B-cell
responses. Such an effect may reflect, at least in part, the
affinity maturation and selective expansion of regulatory T cells
during transient infection with the recombinant Salmonella
strain (6).
The lack of a relevant ETEC animal model has restricted
efficacy studies of potential vaccines prior to volunteer admin-
istration, a step that is not feasible for most vaccine research
laboratories in the world. In an attempt to evaluate the pro-
tective efficacy of the proposed ETEC vaccine regimen, we
adapted a previously described neonate challenge model (10)
for a human-derived ETEC strain. Based on that model, we
demonstrated that serum antibodies raised in mice subjected
to the DNA primer-Salmonella booster vaccine regimen con-
ferred enhanced protection levels (82%) to newborn DBA2
mice who were lethally challenged with a CFA/I ETEC strain.
As expected, sera from mice who were immunized only with
the DNA vaccine did not confer any protection to the inocu-
lated mice, due to the generation of antibodies that were un-
able to bind and neutralize surface-exposed epitopes required
for the binding of the CFA/I fimbriae to host cell receptors (1).
Such observations further suggest that antibodies raised in
mice subjected to the combined vaccine regimen both quanti-
tatively and qualitatively improve the elicited antibody re-
sponses. Nonetheless, a definite demonstration of the protec-
tive potential of the proposed vaccine regimen will require
additional testing with appropriate animal models, such as the
removable intestinal tie-adult rabbit diarrhea model (38), or
the enrollment of human volunteers in a vaccine trial.
So far, vaccines against ETEC-associated diarrhea have
been mainly restricted to inactivated ETEC strains producing
different colonization factors and to attenuated Salmonella or
Shigella strains that have been genetically modified to express
ETEC CFAs (3, 16). The present results indicate that a vaccine
regimen based on priming with a DNA vaccine followed by
boosting with a recombinant Salmonella strain expressing the
same ETEC fimbrial protein can be an alternative for the
development of ETEC vaccines based on the primer-booster
concept, a vaccine approach which has been successfully used
against several virus- and parasite-associated diseases. Con-
structions based on multiepitope DNA vaccines or the combi-
nation of several plasmids encoding different proteins is feasi-
ble and may help us to develop multitarget vaccines aiming for
the control of ETEC colonization as well as infections with
pathogens with heterogenous antigen compositions.
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